Holen Sie sich die Stockscreener-App
4.10
9.09%
-0.41
Handel nachbörslich:
4.10
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CAMP?
Forum
Prognose
Aktiensplit
Camp 4 Therapeutics Corp Aktie (CAMP) Neueste Nachrichten
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Sahm
CAMP Technical Analysis | Trend, Signals & Chart Patterns | CAMP4 THERAPEUTICS CORP (NASDAQ:CAMP) - ChartMill
Camp4 Therapeutics Corp CEO unveils gene expression strategy with regRNA for rare disease therapy - Traders Union
Camp4 studies CMP-002 in SYNGAP1 haploinsufficient mouse model - BioWorld News
Balyasny Asset Management (CAMP) reports 2.63M shares; 4.99% warrant blocker - Stock Titan
CAMP4 Therapeutics Reports Preclinical Success of CMP-002 in Reducing Seizures for SYNGAP1-Related Disorder, Plans Phase 1/2 Trial in 2026 - Minichart
CAMP4 Highlights Preclinical Progress of SYNGAP1 Therapy - TipRanks
CAMP4 reports positive preclinical seizure data for CMP-002 - Investing.com
Camp4 Therapeutics Corp unveils new preclinical data on SYNGAP1 seizure model in Boston - Traders Union
CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder - The Manila Times
CAMP4 Therapeutics to Present New Preclinical Data - GlobeNewswire
Camp4 Therapeutics Corp targets capital discipline with new R and D focus - Traders Union
CAMP4 Therapeutics Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Camp4 Therapeutics Corp posts Q1 2026 financial results and reveals corporate developments - Traders Union
CAMP4 Therapeutics Corporation (CAMP) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Rare-disease drug moves toward human trial as CAMP4 projects cash into 2028 - Stock Titan
CAMP4 Therapeutics (NASDAQ: CAMP) details Q1 2026 results and cash runway into 2028 - Stock Titan
Camp4 Therapeutics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
CAMP4 Therapeutics (CAMP) posts Q1 2026 loss but keeps cash runway into 2028 - Stock Titan
CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights - GlobeNewswire
CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Short Interest in CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Expands By 13.1% - MarketBeat
Camp4 Therapeutics Corp engages with SYNGAP1 families to inform regRNA therapeutic progress - Traders Union
CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation - The Manila Times
CAMP4 maps thousands of new RNAs for gene-boosting drugs - Stock Titan
Camp4 Therapeutics shares slide after $30 million equity offering priced - MSN
CAMP4 (CAMP) details director votes, auditor ratification and equity plan - Stock Titan
[ARS] Camp4 Therapeutics Corp SEC Filing - Stock Titan
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sahm
CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Short Interest Down 14.2% in March - MarketBeat
Three new CAMP4 hires get stock options at $4.59 a share - Stock Titan
Camp4 Therapeutics Corp boosts team engagement with employee event on the slopes - Traders Union
CAMP4 Therapeutics (NASDAQ:CAMP) Upgraded to "Strong-Buy" at Rodman & Renshaw - MarketBeat
CAMP4 (CAMP) Stock: Market Pricing (Drifts Higher) 2026-04-15Community Hot Stocks - Newser
Rodman & Renshaw initiates CAMP4 Therapeutics stock with buy rating By Investing.com - Investing.com Australia
Rodman & Renshaw initiates CAMP4 Therapeutics stock with buy rating - Investing.com
CAMP4 Therapeutics Unveils Gene-Upregulation ASO Platform, Targets SYNGAP1 Clinic Entry in 2H - MarketBeat
Life sciences leaders unite at Camp4 Therapeutics Corp-backed event supporting health equity - Traders Union
CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Camp4 Therapeutics Corp advances creative strategies in complex drug discovery partnerships - Traders Union
Is CAMP4 (CAMP) Stock Good for Beginners | Price at $4.72, Up 5.59%Trending Momentum Stocks - Newser
Camp4 Therapeutics (CAMP) grants 170,000 stock options to Chief Scientific Officer - Stock Titan
Camp4 Therapeutics (CAMP) CMO receives 215,000 stock options grant - Stock Titan
Camp4 Therapeutics (CAMP) CFO receives 215,000 stock options grant - Stock Titan
Camp4 Therapeutics Corp (CAMP) CEO granted 580,000 stock options at $4.46 - Stock Titan
Camp4 Therapeutics (CAMP) director awarded 56,000 stock options at $4.46 strike - Stock Titan
Camp4 Therapeutics (CAMP) director Michael MacLean files initial Form 3 - Stock Titan
Amazon To Rally Around 45%? Here Are 10 Top Analyst Forecasts For Thursday - Sahm
CAMP Stock Analysis: CAMP4 Therapeutics Corporation biotech performance at 4.47 - Newser
Leerink raises CAMP4 Therapeutics price target on CMP-002 progress By Investing.com - Investing.com South Africa
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):